Literature DB >> 26044066

The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.

Christoffer Bjerre Haase1, Vibeke Backer1,2, Anders Kalsen1, Sebastian Rzeppa3, Peter Hemmersbach3, Morten Hostrup1,2,4.   

Abstract

The present study investigated the influence of exercise and dehydration on the urine concentrations of salbutamol after inhalation of that maximal permitted (1600 µg) on the 2015 World Anti-Doping Agency (WADA) prohibited list. Thirteen healthy males participated in the study. Urine concentrations of salbutamol were measured during three conditions: exercise (EX), exercise+dehydration (EXD), and rest (R). Exercise consisted of 75 min cycling at 60% of VO2max and a 20-km time-trial. Fluid intake was 2300, 270, and 1100 mL during EX, EXD, and R, respectively. Urine samples of salbutamol were collected 0-24 h after drug administration. Adjustment of urine concentrations of salbutamol to a specific gravity (USG) of 1.020 g/mL was compared with no adjustment. The 2015 WADA decision limit (1200 ng/mL) for salbutamol was exceeded in 23, 31, and 10% of the urine samples during EX, EXD, and R, respectively, when unadjusted for USG. When adjusted for USG, the corresponding percentages fell to 21, 15, and 8%. During EXD, mean urine concentrations of salbutamol exceeded (1325±599 ng/mL) the decision limit 4 h after administration when unadjusted for USG. Serum salbutamol Cmax was lower (P<0.01) for R(3.0±0.7 ng/mL) than EX(3.8±0.8 ng/mL) and EXD(3.6±0.8 ng/mL). AUC was lower for R (14.1±2.8 ng/mL·∙h) than EX (16.9±2.9 ng/mL·∙h)(P<0.01) and EXD (16.1±3.2 ng/mL·∙h)(P<0.05). In conclusion, exercise and dehydration affect urine concentrations of salbutamol and increase the risk of Adverse Analytical Findings in samples collected after inhalation of that maximal permitted (1600 µg) for salbutamol. This should be taken into account when evaluating doping cases of salbutamol.
Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  WADA; beta2-adrenoceptor agonists; doping; pharmacology; urine specific gravity

Mesh:

Substances:

Year:  2015        PMID: 26044066     DOI: 10.1002/dta.1828

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  4 in total

1.  The Effect of 1600 μg Inhaled Salbutamol Administration on 30 m Sprint Performance Pre and Post a Yo-Yo Intermittent Running Test in Football Players.

Authors:  Michele Merlini; Marco Beato; Samuele Marcora; John Dickinson
Journal:  J Sports Sci Med       Date:  2019-11-19       Impact factor: 2.988

2.  Model-based meta-analysis of salbutamol pharmacokinetics and practical implications for doping control.

Authors:  Perrine Courlet; Thierry Buclin; Jérôme Biollaz; Irene Mazzoni; Olivier Rabin; Monia Guidi
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-22

3.  Pharmacokinetics of Oral and Inhaled Terbutaline after Exercise in Trained Men.

Authors:  Anders Dyreborg; Nanna Krogh; Vibeke Backer; Sebastian Rzeppa; Peter Hemmersbach; Morten Hostrup
Journal:  Front Pharmacol       Date:  2016-06-10       Impact factor: 5.810

4.  Futility of current urine salbutamol doping control.

Authors:  Jules A A C Heuberger; Sven C van Dijkman; Adam F Cohen
Journal:  Br J Clin Pharmacol       Date:  2018-06-03       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.